COMMUNIQUÉS West-GlobeNewswire

Phonak unveils Virto R Infinio: the compact rechargeable hearing aid designed for today's active lifestyle
12/08/2025
STÄFA, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Phonak , a global leader in hearing care solutions is excited to introduce the Virto R Infinio, its most compact rechargeable custom in-the-ear (ITE) hearing aid [...]
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
12/08/2025
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support global Sandoz [...]
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
12/08/2025
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024 Cash and cash equivalents of €161.3 million at end of June 2025 Further clinical and regulatory progress 2025 financial outlook [...]
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités
12/08/2025
Chiffre d’affaires de 97,6 millions d’euros contre 70,8 millions d’euros au premier semestre 2024 Trésorerie de 161,3 millions d’euros à fin juin 2025 Poursuite des avancées cliniques et réglementaires Confirmation des [...]
iPETcertum™ by Claritas, Developed with Cutting-Edge Technology for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives FDA Clearance
12/08/2025
LONDON and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art signal processing, quantification and AI technologies [...]
Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025
12/08/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025 Financial results for [...]
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
12/08/2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes [...]
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
12/08/2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“ Revive ” or the “ Company ”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
11/08/2025
Posts Positive Organic Growth and Adjusted EBITDA ‎ 1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ Company ”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based [...]
Anteris Announces Results for the Second Quarter of 2025
11/08/2025
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
11/08/2025
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public [...]
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
11/08/2025
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and [...]
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
11/08/2025
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease [...]
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
11/08/2025
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million [...]
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
11/08/2025
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced [...]
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
11/08/2025
$5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN [...]
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
11/08/2025
FDA PDUFA goal date of   August   15 , 2025, for TNX ‑ 102   SL for fibromyalgia: if approved by FDA, TNX ‑ 102   SL would be the first new drug for fibromyalgia in more than 16   years   In   June   2025, the Company [...]
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for [...]
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
11/08/2025
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume [...]

Pages